Janux Therapeutics, Inc. (JANX) P/S ratio
Janux Therapeutics, Inc. (JANX) trades at 66.4× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 85.5×. That is 68.5% lower than the 271.8× of fiscal 2024. Figures as of 18 Nov 2026, 10:33 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/S ratio today
- 66.4×
- P/S ratio, fiscal 2025
- 85.5×
- Change on fiscal 2024
- −68.5%
- Highest on record
- 271.8×fiscal 2024
- Lowest on record
- 58.4×fiscal 2023
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Janux Therapeutics, Inc. P/S ratio, in more detail
Today's figure is 22.4% below the fiscal 2025 year-end.
Across the 4 fiscal year-ends on record (2022–2025), the highest was 271.8× in fiscal 2024 and the lowest 58.4× in fiscal 2023. Today's P/S ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 74.5×.
P/S ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Janux Therapeutics, Inc. P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| Today | 66.4× | — | $10.71 | — | |
| 2025 | 85.5× | 68.5% down | $13.80 | $0.16 | |
| 2024 | 271.8× | 365.2% up | $53.54 | $0.20 | |
| 2023 | 58.4× | 7.9% down | $10.73 | $0.18 | |
| 2022 | 63.4× | — | $13.17 | $0.21 | |
| 2021 | — | — | $19.73 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
Janux Therapeutics, Inc., figure by figure
- Janux Therapeutics, Inc. market cap
- Janux Therapeutics, Inc. revenue
- Janux Therapeutics, Inc. earnings
- Janux Therapeutics, Inc. earnings per share (EPS)
- Janux Therapeutics, Inc. P/E ratio
- Janux Therapeutics, Inc. P/B ratio
- Janux Therapeutics, Inc. free cash flow
- Janux Therapeutics, Inc. operating margin
- Janux Therapeutics, Inc. dividend
- Janux Therapeutics, Inc. shares outstanding
- Janux Therapeutics, Inc. total debt
- Janux Therapeutics, Inc. cash on hand
- Janux Therapeutics, Inc. total assets
- Janux Therapeutics, Inc. return on equity (ROE)
- Janux Therapeutics, Inc. return on invested capital (ROIC)
Janux Therapeutics, Inc. (JANX) overview: price, valuation and scorecard
Janux Therapeutics, Inc. P/S ratio: questions and answers
What is Janux Therapeutics, Inc.'s P/S ratio?
Janux Therapeutics, Inc. (JANX) trades at 66.4× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 85.5×. That is 68.5% lower than the 271.8× of fiscal 2024.
Is Janux Therapeutics, Inc.'s P/S ratio high or low compared with its own history?
Today's P/S ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 74.5×.
What are the highest and lowest P/S ratio figures on record for Janux Therapeutics, Inc.?
Across the 4 fiscal year-ends on record (2022–2025), the highest was 271.8× in fiscal 2024 and the lowest 58.4× in fiscal 2023.
How is Janux Therapeutics, Inc.'s P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Janux Therapeutics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Janux Therapeutics, Inc. (JANX) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/JANX/ps-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.